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Abstract: Modern vaccinology has increasingly focused on non-living vaccines, which are more
stable than live-attenuated vaccines but often show limited immunogenicity. Immunostimulatory
substances, known as adjuvants, are traditionally used to increase the magnitude of protective
adaptive immunity in response to a pathogen-associated antigen. Recently developed adjuvants
often include substances that stimulate pattern recognition receptors (PRRs), essential components
of innate immunity required for the activation of antigen-presenting cells (APCs), which serve as
a bridge between innate and adaptive immunity. Nearly all PRRs are potential targets for adjuvants.
Given the recent success of toll-like receptor (TLR) agonists in vaccine development, molecules
with similar, but additional, immunostimulatory activity, such as defective interfering particles
(DIPs) of viruses, represent attractive candidates for vaccine adjuvants. This review outlines some
of the recent advances in vaccine development related to the use of TLR agonists, summarizes the
current knowledge regarding DIP immunogenicity, and discusses the potential applications of DIPs
in vaccine adjuvantation.
Keywords: defective interfering particles; defective viral genomes; innate immunity; vaccine
adjuvants; pattern recognition receptor agonists
1. Making Better Vaccines; Vaccine Adjuvants
Vaccines have proved to be one of the most successful medical interventions ever implemented;
some of the greatest success stories in public health are attributed to vaccination, such as the worldwide
eradication of smallpox and the near-elimination of poliovirus. Modern vaccines act by inducing
a protective adaptive immune response to a pathogen-associated antigen by mimicking the naturally
occurring immune response to a disease-causing pathogen but without causing disease. The initiation
of innate immunity and the activation of specialized antigen-presenting cells (APCs) pave the
way to a pathogen-specific long-lasting adaptive immune response. Traditionally, vaccines have
comprised either live-attenuated variants of the targeted pathogen or non-living antigens, ranging
from inactivated/killed pathogens to recombinant antigens [1]. Live-attenuated vaccines have good
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immunogenicity and are safe for most recipients; however, these types of vaccines can cause disease
when administered to individuals with an unrecognized immunodeficiency and they also exhibit
a potential of reversion to virulence [2]. Non-living antigen vaccines are safer for immunocompromised
individuals but are often poorly immunogenic. Immunostimulatory substances, known as adjuvants,
help increase vaccine immunogenicity and have been used in human vaccines for more than 80 years.
Aluminum salts were the first adjuvant used in human vaccines in 1932 [3,4], and novel adjuvants
have been introduced in vaccine formulations only in the last two decades [5,6]. The improvements in
vaccine immunogenicity when an antigen is co-administered with an adjuvant are exemplified by the
case of influenza A virus subtype H5N1 pandemic vaccines [7]. Compared to non-adjuvanted and
alum-adjuvanted vaccines, oil-in-water emulsions (MF-59) have conferred significant adjuvant effects
on inactivated H5N1 pandemic influenza vaccines in humans, inducing improved immunogenicity
in all age ranges and cross-reactive immune protection against H5 subtype clades as well as sparing
antigen, thereby allowing an effective increase in supply [5]. The H5N1 experience illustrates that
vaccine immunogenicity can be remarkably improved when vaccines are administered with the
appropriate adjuvant. Despite great advances in vaccine efficacy and implementation over the past
several decades, infectious diseases remain the most important cause of childhood mortality [8],
while respiratory infections, diarrhea and tuberculosis all rank in the top ten leading causes of
death across all age groups [9]. The most important challenges in vaccine development are linked
to (i) complex pathogens, such as those that cause immune dysfunction in the host (e.g., human
immunodeficiency virus; HIV), those with complex life cycles (e.g., malaria) or those with a latent
disease phase (e.g., Mycobacterium tuberculosis), and (ii) high-risk populations, such as infants (immature
immunity), the elderly (immunosenescence), and chronically diseased or immunocompromised
individuals (reviewed by DiPasquale et al. [10]). Recent advances in immunology, especially a greater
understanding of the link between innate and adaptive immunity, allow the development of novel
adjuvants that can selectively activate immunological pathways to obtain the desired immune response
against a specific pathogen in distinct target populations.
Adjuvants can augment the immune response to vaccines through a variety of mechanisms, including
deposition of vaccine (antigen) and the activation of innate immunity. Early innate immunity constitutes
the first line of defense against pathogen invasion. Early pathogen recognition plays a crucial role in
the subsequent triggering of a proinflammatory response to the invading pathogen while orchestrating
pathogen-specific adaptive immune responses. Adjuvants can stimulate innate immunity by interacting
with cellular pattern recognition receptors (PRRs), which detect pathogen-associated molecular patterns
(PAMPs), distinct, evolutionarily conserved structures on pathogens [11]. Currently, several PRRs have
been identified, including the well-characterized toll-like receptors (TLRs), retinoic acid-inducible gene I
(RIG-I)-like receptors (RLRs), nucleotide-binding oligomerization domain NOD-like receptors (NLRs),
C-type lectin receptors (CLRs) and the recently described cytosolic DNA sensors (CDSs) [12]. APCs, such
as dendritic cells (DCs), express a repertoire of PRRs, allowing the recognition of a range of pathogenic
constituents. Upon PAMP engagement, PRRs trigger complex signal cascades that lead to the production
of an appropriate set of cytokines and chemokines, including interferons (IFNs), the enhancement of
antigen presentation capacity and the migration of DCs to lymphoid tissues, where the DCs interact with
T cells and B lymphocytes to initiate and shape the adaptive immune response. The matured DCs are also
endowed with the ability to stimulate naive CD4+ T cells into different T helper (Th) subsets (e.g., Th1
and Th2 cells), which provide help to B cells to facilitate antibody production [13]. The differentiation of
Th cells is regulated by several cytokines; for example, the development of naive CD4+ T lymphocytes
into Th1 cells is regulated by a number of cytokines including IL-12, IL-15 and IL-27 [14]. In brief, a Th1
response primarily develops following infection with intracellular pathogens, such as viruses and some
bacteria, whereas Th2 cells predominate in response to large extracellular parasites [15]. Since most
licensed adjuvants induce a Th2-type response rather than a Th1-type response [16], a current challenge
is to develop adjuvants that induce a strong Th1 bias to increase the efficacy of vaccination against
intracellular pathogens, such as HIV and malaria.
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PRR agonists have been in the spotlight recently because of their profound immunostimulatory
effects, which are associated with the induction of innate immunity. The nature of innate immunity is
coupled with subsequent adaptive immunity; consequently, activators of PRRs, such as TLR agonists
and poly(I:C) (reviewed below), can enhance or even tailor the immunogenicity of a given vaccine and
are, therefore, considered promising molecules for developing new vaccine adjuvants. Furthermore,
PRR agonists may be utilized as alternative forms of prophylactic or therapeutic agents to combat
infectious diseases [13,17]. Defective interfering particles (DIPs) are mutant virus particles that contain
defective virus genomes (DVGs), a subset of which are powerful activators of innate immunity
Indeed, DIPs of negative-sense RNA viruses are critical danger signals for viral infection, because
these particles specifically stimulate RLR signaling and, therefore, their presence instigates powerful
antiviral immunity. The evident immunostimulatory activity of DIPs led to the study of defective viral
particles as narrow- or broad-spectrum antivirals (reviewed by Dimmock et al. [18]) and also as vaccine
adjuvants. In this review, we discuss the importance of innate immunity in acquiring pathogen-specific
adaptive immunity, how PRR agonists are being developed as vaccine adjuvants, and how virus DIPs
and DVGs offer advantages for the enhancement of immune responses.
2. Pattern Recognition Receptor Agonists: A Diverse Class of Vaccine Adjuvants
Recent advances in the study of innate immune receptors and their ligands has laid the foundation
for the development of a series of novel immunoenhancers, a number of which are currently approved
for human use (Figure 1). Given that TLRs are the most extensively characterized class of PRRs, it is not
surprising that most adjuvants in clinical use target TLRs (comprehensively reviewed by others [19–22]).
Ten TLRs have been identified in humans and are categorized into two groups: those located at the cell
membrane and the intracellular TLRs, which are expressed on the membrane of endocytic vesicles or
other intracellular organelles [23,24]. TLR4 is unique among TLRs as it initiates pathways in different
cellular locations including the cell membrane and intracellular compartments. The location of TLRs is
directly associated with the type of microbial PAMPs they recognize. For instance, TLRs expressed
on the cell membrane sense microbial membrane components, including lipids and flagella, whereas
TLRs expressed in intracellular vesicles sense microbial nucleic acids, including double-stranded RNA
(dsRNA), single-stranded RNA (ssRNA) and CpG DNA motifs [25] (Figure 1).
TLR-based adjuvants mimic PAMP(s) generated during a natural infection and, therefore, can be
highly effective against pathogens or diseases that naturally activate the associated PRRs. For instance,
TLRs play a vital role in the control of hepatitis B virus (HBV) infections in vivo, specifically by
activating antiviral innate immune responses and modulating HBV-specific adaptive immunity, which
is crucial for terminating the virus infection [26]. Natural or synthetic ligands of several TLRs are
present in licensed human vaccines, or are currently being tested in clinical trials, as adjuvants in
various vaccine formulations. These are ligands of either surface TLRs (e.g., TLR4 and TLR5) or
ligands of endosomal TLRs (e.g., TLR7/8 and TLR9) (Figure 1). The adjuvant system 04 (AS04)
represents one of the most successful adjuvant systems currently present in two registered vaccines:
Fendrix, the HBV vaccine [5], and Cervarix, the human papillomavirus (HPV-16/18) cervical cancer
vaccine [27]. AS04 combines aluminum salts and the TLR4-agonist 3-O-deacylated-4′-monophosphoryl
lipid A (MPLA), a detoxified derivative of lipopolysaccharide (LPS) with retained immunostimulatory
capacity [28]. More specifically, MPLA stimulates a polarized Th1 cell response, in contrast to
the mixed Th1-Th2 cell response of aluminum salts alone [29,30], and induces considerably fewer
pro-inflammatory cytokines than the parent LPS molecule [31]. In addition to AS04, the AS01 and
AS02 adjuvant systems also consist of MPLA but in combination with Quillaja saponaria Molina fraction
21 (saponin QS-21) and a liposomal suspension (AS01) or an oil-in-water emulsion (AS02) [28]. AS01
is present in Mosquirix, the first malaria vaccine to be approved for immunization against Plasmodium
falciparum [32]. Although AS02 was the first adjuvant to be tested in trials as an adjuvant for the malaria
vaccine, AS01 induced better antigen-specific immunity to the P. falciparum circumsporozoite (CS) and
was therefore selected for use in Mosquirix [33,34]. Several clinical trials are presently investigating the
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adjuvant activity of AS01 and AS02 in vaccines against HIV, tuberculosis, HBV and malaria. In addition
to these MPLA-based adjuvant systems, MPLA has also been approved for use in an allergy vaccine,
namely, Pollinex Quattro. Specifically, MPLA triggers a Th1-type immune response characterized
by an increase in allergen-specific antibody levels when administered to patients suffering from
seasonal allergic rhinitis [35]. Pollinex Quattro is in clinical use against seasonal allergic rhinitis in
some countries, and ongoing clinical trials are also evaluating MPLA as a potential adjuvant for
vaccines targeting other pathogens, including leishmania parasites and herpes virus [20]. In addition,
aminoalkyl glucosaminide 4-phosphates (AGPs) represent a new class of synthetic lipid A analogs that
can be manufactured at high purity as single chemical units, unlike MPLA [36]. RC-529 (also known as
Ribi.529) belongs to the AGP family and is a fully synthetic monosaccharide mimetic of MPLA. Notably,
RC-529 increased the immunogenicity of the human HBV recombinant vaccine Supervax, compared
with that of the aluminum-adjuvanted version of the vaccine [37]. Supervax has an acceptable safety
profile and is approved for vaccination against HBV in Argentina [37].Viruses 2017, 9, 186    4 of 17 
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Figure 1. Pattern recognition receptor (PRR) agonists u ed as vaccine adjuvants in the clinic or in cli ical
trials ( ot an exhaustiv list) ref renced in the manuscript. For simplicity, figure shows TLR4 only
on cell membrane, however TLR4 can signal both at cell membrane and endosomes. Abbreviations:
PRR, Pattern recognition receptor; RLRs, RIG-I-like receptors; TLRs, Toll-like receptors; pppRNA,
triphosphate-RNA; dsRNA, double-stranded RNA; LPS, lipopolysaccharide; ssRNA, single-stranded
RNA; CpG-ODNs, CpG-containing oligonucleotides; poly(I:C), polyinosinic:polycytidylic acid; MPLA,
monophosphoryl lipid A; AS, adjuvant system; HBV, hepatitis B virus; HPV, human papillomavirus.
Several other TLR ligands have sho n promising adjuvant activity in clin cal trials (Figure 1).
Imiquimod (R837) belongs to the imidazoquinoli e family and is a small synthetic compound
recognized by the TLR7 receptor in e dosomes. Imiquimod has been successfully used to treat
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HPV-induced genital warts and certain skin cancers under the brand name of Aldara [38]. The use
of imiquimod as a vaccine adjuvant is still under investigation; however, a recent clinical trial has
demonstrated that pretreatment with topical imiquimod significantly enhances the immunogenicity
of the intradermal trivalent influenza vaccine [39]. Likewise, synthetic oligonucleotides (ODNs)
harboring CpG motifs (CpG-ODNs) elicit potent immunostimulatory responses through TLR9 and
have shown promising adjuvant activity in both experimental and clinical settings. The immune
effects of CpG-ODNs result from the activation of TLR9s expressed on DCs and B cells, which
subsequently stimulate several aspects of innate and adaptive immunity, including the production
of IFNs and pro-inflammatory cytokines (IL-6, TNF-α), activation of natural killer (NK) cells,
and differentiation of Th1 immune cells [40]. CpG-ODNs have improved the immunogenicity of
a commercially available HBV vaccine (Engerix-B) [41], increased the antigen-specific immune
responses against anthrax [42], and demonstrated promising activity as an immunotherapy for the
treatment of cancer [43]. Numerous ongoing clinical trials are investigating the therapeutic potential
of CpG-ODNs as adjuvants for vaccines targeting cancer, infectious diseases and allergies [20]. Lastly,
flagellin, the main constituent of bacterial flagella, is potently recognized by cell surface TLR5 and has
shown promising immunoenhancing activity in novel formulations of influenza vaccines. Specifically,
recombinant influenza vaccines comprising flagellin fused to influenza antigens [e.g., matrix protein
2 (M2; VAX102) or hemagglutinin (HA; VAX128)] resulted in high antibody titers, seroconversion
and protection [44,45]. Flagellin-adjuvanted recombinant influenza vaccines therefore represent
a promising next-generation vaccine technology.
Several synthetic dsRNAs have also been designed to mimic the natural dsRNA ligands of
PRRs, such as RLRs and TLR3 (Figure 1). Among them, polyinosinic:polycytidylic acid (polyI:C) is
a potent activator of the type I IFN response [46], representing a promising immunostimulatory
candidate for vaccines. Poly(I:C) signaling is primarily dependent on TLR3 and MDA-5 and
strongly drives cell-mediated immunity and the production of type I IFNs [47,48]. Although
polyI:C is highly effective in modulating innate immunity, it was demonstrated early on that
human serum has a relatively high level of enzymatic activity that causes poly(I:C) hydrolysis
and inactivation [49]. Based on this phenomenon, poly-ICLC, a derivative of polyI:C stabilized
with poly-L-lysine and carboxymethylcellulose, has improved pharmacokinetic properties while
maintaining the immunostimulatory activity of the parental molecule [50]. Poly(I:C)/poly-ICLC
elicits strong Th1 immune responses in mice and nonhuman primates [51,52]. Notably, type I IFN
signaling through the IFN receptor (IFNAR) is required for poly(I:C) to establish Th1 responses to
a DC-targeted HIV gag protein vaccine in mice [51,53]. Because type I IFNs have been linked to
the activation of Th1 responses while serving as counter-regulators of Th2 differentiation (reviewed
by Huber et al. [14]), it is believed that the ability of synthetic dsRNAs to induce Th1 immunity is
related to their well-documented ability to induce IFNs. The effectiveness of polyI:C/poly-ICLC as
an HIV vaccine adjuvant is still under investigation; numerous clinical studies are also investigating
the efficacy and tolerability of poly-ICLC as an anti-retroviral agent.
Early innate immunity plays a significant role in controlling tumor progression; for this reason,
PRR agonists have also been actively pursued for their anti-tumor properties and therapeutic
potential as adjuvants for cancer vaccines. Current evidence suggests that type I IFN signaling
participates in innate recognition of tumors and subsequently leads to a functional tumor-associated
antigen (TAA)-specific T cell immunity [54,55]. In fact, spontaneous anti-tumor immunity is likely
to be related to damage-associated molecular patterns (DAMPs), which are molecules that are
usually released by dying or dead cells as a signal of danger. Such cancer-derived DAMPs can be
recognized by PRR receptors on innate immune cells, which subsequently trigger innate immunity [56].
Therefore, the idea of stimulating PRR receptors to potentiate anti-tumor immunity has been eagerly
embraced by tumor immunologists, and poly(I:C)/poly-ICLC is currently considered one of the most
promising immunotherapeutic agents for improving cancer immunotherapy outcomes. The addition of
poly(I:C)/poly-ICLC as a single adjuvant to different cancer vaccine formulations enhances the induction
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of TAA-specific T cell immunity to several tumor types, such as lymphomas, melanomas and lung cancer
tumors, demonstrating promising adjuvant activity for immunotherapies [57]. The anti-tumor activity of
poly(I:C)/poly-ICLC is being tested in ongoing clinical trials [58–60] and has been shown to be safe in
humans [61]. In addition to poly(I:C)/poly-ICLC, a novel RNA-based PRR agonist (RNAdjuvant®) has
also proven to have potent immunostimulatory effects for cancer vaccines [62] and will be employed in
the therapeutic cancer vaccine formulation developed by the HEPAVAC Consortium to specifically target
liver cancer [63]. Taken together, the results from clinical studies substantiate the ability of synthetic PRR
agonists to initiate anti-tumor immune responses in combination with cancer vaccines, increasing their
potential application in future therapeutic interventions.
Despite the evident immunostimulatory activity of PRR agonists, the use of such molecules as
vaccine adjuvants still has several limitations. The cost of manufacturing, especially for synthetic
agonists such as synthetic dsRNAs, remains a major limitation for their future clinical application.
Expensive adjuvants increase vaccine pricing, which can limit vaccine’s worldwide distribution.
Moreover, for intracellular PRR agonists, efficient delivery to target cells is vital for maximal adjuvant
activity, as inefficient internalization would diminish their ability to activate PRR receptors. In currently
used adjuvant systems, this issue is addressed by combining intracellular PRR agonists with carrier
systems (such as liposomes and nanocarriers) [19]. This approach appears to improve the effect of the
ligands by facilitating their internalization and thus potentiating their activity. Furthermore, since most
of current PRR agonists target TLRs, the immune effects of these molecules are essentially restricted
to immune cells, where TLRs are ubiquitously expressed. Regardless, it has been unambiguously
illustrated that PRR agonists are reliable microbial mimics that efficiently stimulate innate immunity
and consequently remain a promising class of new adjuvant candidates that is being further explored.
3. The Immunostimulatory Activity of Defective Interfering Particles of Negative-Sense
RNA Viruses
Given the diversity of PRRs and the large number of their possible ligands, only a small portion of
PRR ligands has been investigated as vaccine adjuvants. Therefore, identifying and understanding the
mode of action of natural PRR agonists, represents a fertile area of research to broaden the molecular
diversity within this class of adjuvants. DIPs of negative-sense RNA viruses are strong activators
of innate immunity and could also represent attractive vaccine adjuvants that, as will be discussed,
may have additional benefits over TLR agonists.
It is believed that DIPs arise spontaneously due to errors made by viral polymerases, however
recent genomic and functional analyses support that DIPs are less likely to be generated randomly.
DIPs contain DVGs, in which at least one gene is deleted, either entirely or sufficiently to cause
a loss of function. The resulting DI viruses are defective for replication because these viruses have
lost an essential gene(s) required for replication and, therefore, only replicate in the presence of
a coinfecting wild-type (“helper”) virus that provides the missing functions [64,65]. DIPs are referred
to as “interfering” because they attenuate the replication of the wild-type virus [66]. Owing to their
smaller size, DVGs have a competitive advantage in replication rate and thus can be synthesized
more rapidly by the viral polymerase; after multiple rounds of replication, the copy number of
DVGs outpaces that of the wild-type virus (reviewed by Marriott et al. [67]). The ability of DIPs to
interfere with wild-type virus replication was first described for the influenza virus in the 1940s [68].
The generation of DIPs has been more extensively studied in RNA viruses since the RNA-dependent
RNA polymerase of these viruses lacks proofreading capacity and is therefore more prone to making
errors during the replication process. However, DIPs are not an exclusive feature of RNA viruses
because potentially all viruses are capable of spontaneously making mistakes during their replication
cycle. DVGs have been isolated from several distinct viral families, including Rhabdoviridae, Togaviridae,
Flaviviridae, Paramyxoviridae, Papillomaviridae, Adenoviridae, Herpesviridae, Tombusviridae, bacteriophages
and many more (reviewed by others [18,69]). Although the accumulation of DVGs was demonstrated
early on in vitro, initial investigations failed to detect DVGs in natural infections, suggesting that
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DVGs are laboratory artifacts. Advances in molecular techniques, especially deep sequencing analysis,
helped overcome technical difficulties in discriminating between wild-type and defective genomes,
leading to the identification of defective genomes in a number of human infections. DVGs were first
identified from patients with viral hepatitis infections [70–72] and were more recently isolated from
patients infected with dengue [73], influenza A virus [74] and respiratory syncytial virus (RSV) [75].
The ability of defective genomes to attenuate standard virus replication, in combination with the
transmissibility of the defective genomes between individuals, underpins the potential role of DVGs in
driving virus-host co-evolution, and perhaps promoting virus persistence. Nonetheless, the biological
role of DIPs in the context of natural infections is still under investigation.
Most of the current understanding of the immunostimulatory activity of DIPs comes from studies
on negative-sense RNA virus DIPs, in particular those of influenza viruses and paramyxoviruses,
including Sendai virus (SeV), parainfluenza virus type 5 (PIV5) and human human respiratory virus
(RSV). The immunogenicity of DIPs generated by other virus classes, such as positive sense ssRNA
(+ssRNA), dsRNA viruses or different types of DNA viruses remains largely unknown, therefore this
review focuses on the immune effects generated by DIPs of negative-sense RNA viruses. Two major
types of DI genomes have been described for negative-sense RNA viruses: (i) copyback DVGs, which
consist of a segment of the viral genome and an authentic terminus followed by an inverted repeat of
this segment and the end sequence [76]; and (ii) DVGs that contain internal deletions but retain their 3′
leader (Le) and 5′ trailer (Tr) sequences and therefore can produce viral translation products [77,78].
A schematic diagram of how internal deletion and copyback DIPs are generated during the replication
of the paramyxovirus PIV5 is shown in Figure 2.
DIPs of negative-sense RNA viruses initiate cellular immune responses by stimulating strong
signaling of intracellular RLRs, namely, RIG-I and melanoma differentiation-associated protein
5 (MDA-5), which are helicases expressed in most cell types [75,79–81] (Figure 3). Several
studies have demonstrated that copyback genomes dominate IFN-inducing DI populations of
paramyxoviruses [80,82–84], suggesting that unique secondary RNA structures present in these short
defective genomes are perhaps driving their immunostimulatory properties. Indeed, although 5-di-
or 5-triphosphates (5′-PPP) coupled to specific single- or double-stranded RNA motifs are known to
trigger RLR signaling, a recent study has identified a natural viral RNA motif (SeV DVG70–114) that
serves as a PAMP enhancer and promotes potent RLR stimulation [85]. Adding a 5′-cap structure or
removing 5′-PPP significantly reduces but does not eliminate the ability of DVGs to induce IFN [83],
indicating that the DVG sequence composition is also critical for effective activation of RLR signaling.
Notably, although influenza viruses have not been reported to generate copyback DVGs, only internal
deletions, influenza DI genomes are also capable of stimulating RIG-I signaling through a mechanism
that remains to be elucidated [86].
The engagement of RLRs is strongly linked to the stimulation of innate immune responses,
especially the production of type I IFNs, which elicit an antiviral function by inducing a wide array
of IFN-stimulated genes (ISGs). In brief, the cellular IFN response is divided into two pathways:
the IFN-induction and IFN signaling pathways. The engagement of PRRs activates a number of
downstream kinases that are essential for the phosphorylation of IFN regulatory factor 3 (IRF3) and
nuclear factor kappa B (NF-κB), which subsequently translocate to the nucleus to induce the IFN
promoter [87]. Following its induction, IFN is secreted from infected cells and binds to the IFN
receptor on the surface of infected or uninfected cells to mediate the activation of the IFN signaling
pathway, which is also known as the Janus-activated kinase (JAK)/signal transducers and activators of
transcription (STAT) signaling pathway [88]. More specifically, engaging the IFNAR with its ligand
causes the phosphorylation of STAT1 and STAT2, which dimerize and translocate into the nucleus.
In the nucleus, STATs bind to IRF9 to form interferon-stimulated gene (ISG) factor 3 (ISGF3), which is
a transcription factor that regulates the expression of hundreds of ISGs. Most ISGs encode products
with discrete antiviral functions, but many ISGs have still not been fully characterised [89].
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of parainfluenza virus 5 (PIV5). Genome structure of PIV5 and its mechanism of transcription (Panel 
A), standard replication (Panel B) and faulty replication that leads to the formation of DVGs (Panel 
C).  PIV5  has  a  negative‐sense  single‐stranded  RNA  genome  15,246  nucleotides  long.  The  PIV5 
genome  encodes  eight  transcription  units,  and  carries  non‐coding  leader  (Le)  and  trailer  (Tr) 
sequences at  its 3′ and 5′  ends,  respectively, which are  essential  for  controlling  transcription and 
replication.  Similar  to  all paramyxoviruses, PIV5  expresses  an RNA‐dependent RNA polymerase 
from the large (L) gene. The viral polymerase recognizes the genomic Le promoter and directs the 
synthesis  of  both  viral  mRNAs  and  antigenomes,  which  comprise  the  exact  full‐length 
complementary  sequence  of  the  genome.  To  produce  separate  mRNAs,  the  polymerase  must 
recognize the gene start (GS) and gene end (GE) signal sequences of each gene. During replication, 
the full‐length antigenomic RNA serves as the template for the synthesis of new genomic RNA from 
the  antigenomic  Tr  promoter.  At  a  high  multiplicity  of  infection,  the  viral  polymerase  loses 
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genome flanked by a reverse complementary version of this segment. Copyback DVGs arise when 
the viral polymerase detaches from the template and reattaches to the nascent strand, which is then 
copied.  The  second  type  of DVG  is  generated when  the  viral  polymerase drops  off  the  original 
template and reattaches further downstream, resulting in a genomic deletion. As a result, these DVGs 
contain internal deletions but retain their 3′ Le and 5′ Tr sequences. 
Figure 2. Schematic representation of defective viral geno e (DVG) generation during the replication
of parainfluenza virus 5 (PIV5). Genome structure of PIV5 and its mechanism of transcription (Panel A),
standard replication (Panel B) and faulty replication that leads to the formation of DVGs (Panel C).
PIV5 has a negative-sense single-stranded RNA genome 15,246 nucleotides long. The PIV5 genome
encodes eight transcription units, and carries non-coding leader (Le) and trailer (Tr) sequences at its
3′ and 5′ ends, respectively, which are essential for controlling transcription and replication. Similar
to all paramyxoviruses, PIV5 expresses an RNA-dependent RNA polymerase from the large (L) gene.
The viral polymerase recognizes the genomic Le promoter and directs the synthesis of both viral
mRNAs and antigenomes, which comprise the exact full-length complementary sequence of the
genome. To produce separate mRNAs, the polymerase must recognize the gene start (GS) and gene
end (GE) sig al sequences of each gene. During re licati n, the full-length antigenomic RNA serves
as the template for the synthesis of new geno ic RNA from th antigenom c Tr ro oter. At a high
multiplicity of inf ctio , the viral polym ase loses processivity, resulting in spontaneous errors. These
errors are r spo sible for the generation of faulty genomes, known as DVGs. There are two major types
of DVGs: copyback DVGs and internal deletions. Copyback DVGs maintain an authentic terminus
(5′ end) and contain a segment of the viral genome flanked by a reverse complementary version of this
segment. Copyback DVGs arise when the viral polymerase detaches from the template and reattaches
to the nascent strand, which is then copied. The second type of DVG is generated when the viral
polymerase drops off the original template and reattaches further downstream, resulting in a genomic
deletion. As a result, these DVGs contain internal deletions but retain their 3′ Le and 5′ Tr sequences.
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Figure 3. Innate and adaptive immune responses to DIPs. DIPs contain truncated forms of viral
genomes, known as DVGs. Copyback DVGs have complementary ends allowing the formation
of double-stranded RNA (dsRNA) structures, which can be recognized by retinoic acid-inducible
gene I (RIG-I)-like receptors (RLRs), namely, RIG-I and melanoma differentiation-associated protein
5 (MDA-5). The stimulation of RLR signaling induces the expression of type I interferons (IFNs)
and several proinflammatory cytokines, which all play key roles in dendritic cell (DC) maturation
and the regulation of adaptive immunity. DVGs enhance the ability of DCs to activate naive T cells,
increase antibody production and direct the immune response toward type 1 T helper (Th1) immunity,
a process requiring type I IFN signaling. DIPs can initiate innate immune responses in many cell
types, including epithelial cells at the site of infection and antigen-presenting cells, such as DCs.
Abbreviations: TNF-α, tumor necrosis factor-alpha; IL-6, interleukin 6; IL-12, interleukin 12; MHC,
major histocompatibility complex.
Considering that DVGs of negative-sense RNA viruses are good activators of RLR signaling, it is
not surprising that DIPs containing these DVGs are also potent inducers of IFNs in cell culture [90–92]
and in vivo [75,80]. Indeed, current evidence suggests that DIPs are primarily responsible for initiating
innate immune responses during paramyxovirus replication. Specifically, SeV DVGs are formed in
the lungs of mice when virus replication peaks, and the presence of these genomes coincides with
the induction of type I IFNs [80]. It has also been demonstrated that a recombinant PIV5 that lacks
a functional V protein (termed PIV5-V∆C), which is the viral IFN antagonist, weakly activates the
cellular IFN response, whereas a DIP-rich preparation of PIV5-V∆C strongly activates the induction
of type I IFNs [92,93]. A recent study has reported that DVGs are the major activators of antiviral
responses in human lungs during RSV infection, signifying the first evidence of an important biological
role for naturally occurri g DVGs during paramyxovirus infections in humans [75]. In some cases,
the antiviral activit of DIPs appears to be highly dependent on the IFN system. For instance, the
broad-spectrum antiviral activity of an influenza A (244 DI virus) is nearly abolished in the
abs nce of the typ I IFN system [94]. Specifically, prec inical studies have demonstrated that the
ability of 244 DI virus to protect mice from non-influenza A respiratory viruses (e.g., pneumonia virus
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of mice and influenza B virus) requires type I IFNs as mice lacking type I IFN receptor were only
poorly protected by the challenge viruses [95,96]. Although type I IFN plays a key role for the 244 DI
virus-mediated antiviral activity against non-related viruses, protection from influenza A viruses does
not entirely depend on type I IFNs, although type I IFNs may contribute to this protection [95,96].
The ability of DVGs of negative-strand viruses to trigger the IFN-induction cascade is not
dependent on virus replication because the DVGs of several paramyxoviruses, including PIV5 and
mumps virus, can induce type I IFNs in the absence of protein synthesis and consequently in the
absence of infectious virus, since protein synthesis is an absolute requirement for paramyxovirus
genome replication [92]. It is, however, possible that the immunostimulatory activity of DVGs requires
RNA synthesis. In this regard, it is notable that it was demonstrated early on that UV-inactivated
Newcastle disease virus (NDV), which had lost infectivity but retained the capacity to induce IFN,
also had the ability to synthesize RNA, while exposure to larger doses of UV radiation abolished the
ability of the virus to either synthesize RNA or induce IFN [97]. These early findings suggest that
the virus-mediated activation of the IFN response requires RNA synthesis, perhaps because newly
synthesized viral RNA serves as a template for the formation of highly immunogenic dsRNA species.
Taken together, the previous studies support the notion that DVGs have an outstanding ability to
stimulate an antiviral response in the presence of highly specific viral antagonists independently of type
I IFNs or virus replication, highlighting that negative-sense RNA virus DIPs are critical determinants
of the outcome of an infection.
DIPs not only activate the cellular IFN response but also stimulate additional aspects of host
immune defense (Figure 3). For instance, DIP-rich SeV preparations can effectively induce the
maturation of mouse and human DCs as measured by the up-regulation of TNF-α, IL-6 and IL-12p40
cytokines, which are indicative of DC maturation [81]. This mechanism is IFN- and TLR-independent
but requires signaling through RIG-I and MDA-5, underscoring the importance of RLR signaling for
DIP immunogenicity [79,81]. SeV DIPs also promote T cell activation by up-regulating the expression
of cluster of differentiation 86 (CD86) and major histocompatibility complex (MHC) II molecules on the
surface of DCs [79,84]. Moreover, an SeV-derived RIG-I agonist (DVG-324) enhances the ability of DCs
to activate specific adaptive immune responses in vivo by stimulating the activation of IFNγ-producing
CD8+ T cells and increasing antibody production [83]. As a result, immunostimulatory DI RNAs
can be successfully used as tools to convert viruses with weak DC maturation abilities into potent
DC stimulators [81,84]. Collectively, DIPs trigger the maturation of DCs and successfully increase
antigen-specific immunity to pathogen-associated antigens.
The adjuvanticity of naturally occurring defective genomes, such as those isolated from SeV
infections, has been investigated both in vitro and in vivo. Specifically, DI RNAs have exhibited
promising adjuvant activity as illustrated by their ability to enhance antibody production and to also
induce Th1 immunity when administered with inactivated vaccines or recombinant antigens [83,84,98].
Notably, a SeV-derived RNA agonist of RIG-I (IVT DI; in vitro-transcribed SeV DI) was found to induce
a Th1-type response, enhancing the immunogenicity of an inactivated influenza A virus subtype H1N1
2009 pandemic vaccine when delivered to mice [84]. Interestingly, recombinant SeV RNAs are naked
RNAs yet still immunostimulatory with an unknown route to RIG-I, an interaction which needs to be
explored further. The positive results obtained from these studies indicate that natural RIG-I agonists
are promising candidate adjuvant molecules that are expected to be further explored to verify their
adjuvant activity in humans.
4. Further Applications of Defective Interfering Particles in Vaccine Adjuvantation
Even though DIPs are powerful initiators of innate immunity, synthetic dsRNAs, including
sequences derived from DVGs of negative-sense RNA viruses, have received greater attention as
vaccine adjuvants, perhaps because these molecules can be easily isolated as non-infectious RNA
moieties. However, large amounts of DIPs have been found in currently used live-attenuated vaccines
of poliovirus, measles virus and current flu vaccines [99–101], suggesting that the efficacy of these
Viruses 2017, 9, 186 11 of 17
vaccines is related to existing DIPs. Shedding more light on the role of these naturally occurring
DI RNAs in vaccine immunogenicity will evaluate their adjuvant activity and perhaps allow their
further development as chemically defined vaccine adjuvants. The major challenge that arises from
supplementing killed/non-replicating vaccines with DIPs is that DIPs preferably should not be
contaminated with parental/infectious virus. One way to achieve this is by propagating DIPs in
complementing cell lines that express the missing viral gene product(s) to support DIP formation and
replication in the absence of infectious virus. In normal cells, these mutant DIPs will be deficient for
replication because their defective genomes will be released in the infected cell without the ability
to copy themselves and generate progeny virus particles [102]. Such recombinant DIPs would be
non-infectious and would have several advantages over currently identified natural or synthetic
dsRNAs. First, DIPs contain all the necessary viral components to naturally penetrate cells, which
internalize the defective genomes and subsequently activate innate immunity through PRR signaling.
DIPs essentially combine immunostimulatory activity and the efficiency of carrier systems. In fact, even
low numbers of PIV5 copy-back DVGs were found to be capable of strongly activating innate immunity
in host cell [93], denoting that DIPs are highly immunogenic. Second, DIPs combine the safety of
killed vaccines and the immunogenicity of live virus vaccines and can be genetically engineered to
trigger the desired immune response against a targeted pathogen. Third, DIPs are still capable of
encapsidating their defective genomes to form highly stable structures. Furthermore, recombinant
DIPs would have one major advantage over currently identified TLR agonists; DIPs (specifically those
generated by -ssRNA viruses) are recognized by RLRs, which are expressed by almost every cell
type [103]. In contrast, human TLRs are ubiquitously expressed in immune cells but less widespread
in cells of non-hematopoietic origin [104]. Consequently, DIPs can be recognized as PAMPs in every
cell they infect and are, therefore, more likely to potentiate high immune responses via different routes
of immunization.
Although DIPs have a viral origin, their applications in vaccine development are not limited to
combating viral diseases. DIPs can be used as immunostimulators in vaccines designed against other
infectious pathogens (such as bacteria and parasites) and potentially diseases such as cancer. Moreover,
given that all viruses, regardless of their genome type (e.g., RNA or DNA, single- or double-stranded,
positive- or negative-sense), are capable of generating DIPs, it is possible that different DIPs may trigger
different types of PRRs depending on DIPs’ viral origin. In this regard, it is interesting to note that
PAMPs generated by DNA viruses, such as the 2′3′-cyclic guanosine monophosphate-adenosine
monophosphate (cGAMP), which is produced by cyclic guanosine monophosphate adenosine
monophosphate synthase (cGAS) in response to the intracellular recognition of DNA, showed great
potential as an adjuvant for cutaneous vaccination in preclinical studies [105]. Briefly, cGAMP binds
the stimulator of interferon genes (STING), which subsequently activates innate immune responses
including the production of type I IFNs [106]. This implies that DIPs could perhaps activate different
aspects of innate immunity, increasing the likelihood of activating the desired immune responses to
a given pathogen. However, this is an area to be explored further. In conclusion, current evidence
supports that DIPs are potent activators of innate immunity and, therefore, DIPs represent promising
immunostimulatory molecules to be further investigated as a novel class of adjuvant candidates.
5. Conclusions
For a variety of reasons, modern vaccinology has increasingly focused on non-living vaccines
that often require the addition of adjuvants to provide stimulatory signals to activate innate immune
responses. However, there is no single set of characteristics that describes an ideal vaccine adjuvant
for all situations. Indeed, vaccine studies using live-attenuated pathogens support the hypothesis
that activating multiple innate receptors is better than activating only one receptor, indicating that
adjuvant combinations may achieve a better effect. Several preclinical and clinical studies are
currently investigating the efficiency of different adjuvant combinations, supporting the view that
multiadjuvanted vaccines could represent the way forward for the design of new vaccine formulations.
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Expanding the repertoire of adjuvants enables the use of different molecular combinations to
activate the desired arms of the immune system and adapt the adjuvant to a given target pathogen
and/or population.
Enhancing vaccine immunogenicity by using appropriate adjuvants will also reduce the amount
of immunogen required to induce protective immunity, potentially increasing the amount of vaccine
that can be manufactured, having important implications for the global vaccine supply, and thereby
reducing the morbidity and mortality of vaccine-preventable diseases (VPDs). In fact, the first aim of
the CDC’s strategic framework for global vaccination for 2016–2020 is to control, eliminate or eradicate
VPDs to reduce death and disability globally [107]. The achievement of this goal will lead to a world
free of polio, the elimination of measles and rubella/congenital rubella syndrome, the control of
other VPDs by vaccine introduction and the development of new vaccination strategies, including
new adjuvant approaches. There is also an important need to develop vaccines with a more defined
composition to improve vaccine acceptance by the public. The lack of trust in vaccines is a growing
threat to the success of global vaccination programs. Vaccine hesitancy, as defined by a delay in the
acceptance or the refusal of vaccines, is held responsible for reducing global immunization coverage
and increasing the risk of VPD outbreaks and epidemics. In this regard, newly designed adjuvants,
including potentially DIPs, with well-defined immunostimulatory activity will accelerate our efforts to
develop a new generation of vaccines with a lower risk-to-benefit ratio.
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